BR0207310A - Composição farmacêutica de interferon gama ou de pirfenidona com diagnósticos moleculares para o melhor tratamento de doenças pulmonares intersticiais - Google Patents

Composição farmacêutica de interferon gama ou de pirfenidona com diagnósticos moleculares para o melhor tratamento de doenças pulmonares intersticiais

Info

Publication number
BR0207310A
BR0207310A BR0207310-2A BR0207310A BR0207310A BR 0207310 A BR0207310 A BR 0207310A BR 0207310 A BR0207310 A BR 0207310A BR 0207310 A BR0207310 A BR 0207310A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
interstitial lung
pirfenidone
molecular diagnostics
interferon gamma
Prior art date
Application number
BR0207310-2A
Other languages
English (en)
Inventor
Dorian Bevec
Rolf Ziesche
Original Assignee
Mondobiotech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mondobiotech Sa filed Critical Mondobiotech Sa
Publication of BR0207310A publication Critical patent/BR0207310A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA DE INTERFERON GAMA OU DE PIRFENIDONA COM DIAGNóSTICOS MOLECULARES PARA O MELHOR TRATAMENTO DE DOENçAS PULMONARES INTERSTICIAIS". A presente invenção refere-se a uma nova composição farmacêutica que compreende interferon-<sym> ou pirfenidona e um arranjo para diagnóstico de polinucleotídeos candidatos para o tratamento melhorado de doenças pulmonares, especialmente para todas as formas de doenças pulmonares intersticiais. Essa invenção descreve a combinação de diagnósticos moleculares e de terapia clínica como um novo princípio de medicação para a redução da mortalidade e melhoria do controle da doença em doenças pulmonares intersticiais.
BR0207310-2A 2001-12-18 2002-12-12 Composição farmacêutica de interferon gama ou de pirfenidona com diagnósticos moleculares para o melhor tratamento de doenças pulmonares intersticiais BR0207310A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01130011 2001-12-18
PCT/CH2002/000691 WO2003051388A2 (en) 2001-12-18 2002-12-12 Pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases

Publications (1)

Publication Number Publication Date
BR0207310A true BR0207310A (pt) 2004-08-17

Family

ID=8179579

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207310-2A BR0207310A (pt) 2001-12-18 2002-12-12 Composição farmacêutica de interferon gama ou de pirfenidona com diagnósticos moleculares para o melhor tratamento de doenças pulmonares intersticiais

Country Status (9)

Country Link
US (2) US20060270618A1 (pt)
EP (1) EP1455813B1 (pt)
JP (1) JP2005528082A (pt)
CN (1) CN1620309A (pt)
AU (1) AU2002347182A1 (pt)
BR (1) BR0207310A (pt)
CA (1) CA2470763A1 (pt)
NO (1) NO20033642L (pt)
WO (1) WO2003051388A2 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
EP1455813B1 (en) * 2001-12-18 2015-07-15 mondoBIOTECH AG Interferon gamma in combination with a diagnostic array for use in the improved treatment of idiopathic pulmonary fibrosis
CA2496577A1 (en) * 2002-08-28 2004-03-11 Intermune, Inc. Combination therapy for treatment of fibrotic disorders
CA2532135A1 (en) * 2003-07-14 2005-01-20 Mondobiotech Laboratories Anstalt Biologically active substance of a vasoactive intestinal peptide for treating interstitial lung infections
EP3184630B1 (en) * 2005-09-23 2019-07-17 TiGenix, S.A.U. Cell populations having immunoregulatory activity, method for isolation and uses
US8425935B2 (en) 2005-12-21 2013-04-23 Basf Se Pharmaceutical formulation for producing rapidly disintegrating tablets
CN101631877A (zh) * 2007-01-09 2010-01-20 百时美施贵宝公司 用于预测可与前列腺细胞中蛋白酪氨酸激酶和/或蛋白酪氨酸激酶途径相互作用和/或对其进行调节的化合物的活性的多核苷酸的鉴定
CA2686964A1 (en) 2007-06-06 2008-12-11 Basf Se Pharmaceutical formulation for the production of rapidly disintegrating tablets
AU2008265595B2 (en) * 2007-06-20 2014-12-04 PureTech LYT 100 Inc. Substituted N-Aryl pyridinones as fibrotic inhibitors
JP5312459B2 (ja) 2007-08-02 2013-10-09 ジリード バイオロジクス，インク． Ｌｏｘおよびｌｏｘｌ２阻害剤ならびにこれらの使用
JP5583592B2 (ja) * 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
WO2010065755A1 (en) 2008-12-04 2010-06-10 Concert Pharmaceuticals, Inc. Deuterated pyridinones
US9107935B2 (en) * 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
AU2010206543A1 (en) * 2009-01-26 2011-07-07 Intermune, Inc. Methods for treating acute myocardial infarctions and associated disorders
WO2011022670A1 (en) * 2009-08-21 2011-02-24 Arresto Biosciences, Inc In vivo screening assays
AU2010284000A1 (en) * 2009-08-21 2012-03-22 Gilead Biologics, Inc. In vitro screening assays
AU2010284036B2 (en) 2009-08-21 2014-12-18 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and LOXL2
RU2012110587A (ru) * 2009-08-21 2013-09-27 Джилид Байолоджикс, Инк. Терапевтические способы и композиции
RU2561672C2 (ru) * 2009-08-21 2015-08-27 Джилид Байолоджикс, Инк. Способы и композиции для лечения фиброзных заболеваний легких
US20120329666A1 (en) * 2009-10-05 2012-12-27 Duke University Peripheral Blood Biomarkers for Idiopathic Interstitial Pneumonia and Methods of Use
SG183174A1 (en) 2010-02-04 2012-09-27 Gilead Biologics Inc Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
EP2580240B1 (en) 2010-06-14 2018-11-28 Lykera Biomed S.A. S100a4 antibodies and therapeutic uses thereof
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
AU2012212269B2 (en) 2011-01-31 2016-05-19 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
DK3460054T3 (da) 2013-03-15 2021-01-18 Atyr Pharma Inc Histidyl-tRNA-syntetase-Fc-konjugater
CN103467612B (zh) * 2013-09-09 2015-06-24 山东省农业科学院农产品研究所 一种从热榨花生粕中同步提取多糖和蛋白的方法
NZ722927A (en) 2014-01-10 2022-07-29 Avalyn Pharma Inc Aerosol pirfenidone and pyridone analog compounds and uses thereof
GB201408100D0 (en) * 2014-05-07 2014-06-18 Sec Dep For Health The Detection method
JOP20200115A1 (ar) * 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
EP3215170A4 (en) 2014-11-05 2018-04-25 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
EP3344283A1 (en) * 2015-08-31 2018-07-11 Merck Patent GmbH Methods for the modulation of lgals3bp to treat systemic lupus erythematosus
CN107356761B (zh) * 2016-05-09 2020-03-31 上海华盈生物医药科技有限公司 接骨木凝集素及结合珠蛋白相关蛋白的用途
TWI783957B (zh) 2016-12-23 2022-11-21 美商伊繆諾金公司 靶向adam9之免疫共軛物及其使用方法
AR110424A1 (es) 2016-12-23 2019-03-27 Macrogenics Inc Moléculas de unión a adam9 y métodos de uso de las mismas
CN106860855B (zh) * 2017-03-01 2021-06-11 成都惠泰生物医药有限公司 多肽及多肽衍生物在预防和治疗纤维化疾病中的应用
CN109384830B (zh) * 2017-08-09 2021-12-03 成都惠泰生物医药有限公司 多肽、多肽片段及其衍生物在防治纤维化疾病中的应用
CA3060514A1 (en) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
CN109722455B (zh) * 2017-10-31 2022-03-11 中国科学院天津工业生物技术研究所 微生物发酵生产谷内酯的方法、工程菌及应用
KR20210061995A (ko) 2018-06-26 2021-05-28 이뮤노젠 아이엔씨 Adam9를 표적으로 하는 면역콘쥬게이트 및 이를 이용하는 방법들
CN111103426B (zh) * 2019-12-19 2022-10-21 广州市妇女儿童医疗中心 Lap3作为儿童腺病毒肺炎诊断标志物的应用
CN113846150A (zh) * 2020-06-28 2021-12-28 深圳华大生命科学研究院 核酸分子及其应用
TW202302155A (zh) 2021-03-08 2023-01-16 美商伊繆諾金公司 用於增加靶向ａｄａｍ９之免疫結合物治療癌症之功效的方法
CN114276418A (zh) * 2021-12-28 2022-04-05 中国科学技术大学 一种可用于调控微管、治疗脱髓鞘病变靶向治疗的rna
CN114452376A (zh) * 2022-01-21 2022-05-10 上海市精神卫生中心（上海市心理咨询培训中心） 胰岛素样生长因子结合蛋白2在制备治疗神经脱髓鞘性疾病的药物中的应用
CN114636825B (zh) * 2022-03-02 2022-12-20 中国医学科学院北京协和医院 Golm1作为肺纤维化生物标记物、靶点的应用及检测Golm1的试剂的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
IE873041L (en) * 1987-11-11 1989-05-11 Ailbe Brennan Viral antigens, diagnostic assay therefor and vaccines¹containing them
WO1990006952A1 (en) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
DK0403333T3 (da) * 1989-06-02 2000-03-20 Pasteur Institut Nukleotidsekvenser stammende fra genomet i retrovirus af typen HIV-1, HIV-2 og SIV og deres anvendelse, fortrinsvis til opf
WO1994026249A1 (en) * 1993-05-07 1994-11-24 Margolin Solomon B Compositions and methods for reparation and prevention of fibrotic lesions
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
ES2093554B1 (es) * 1995-02-17 1997-07-01 Inst De Salud Carlos Iii Procedimientos de amplificacion de genoma y mezclas de oligonucleotidos iniciadores para la deteccion y la identificacion de agentes infecciosos relacionados.
EP0795332B1 (en) * 1996-03-14 2005-06-01 Mondobiotech Interferon SA Medical use of gamma-interferon in interstitial lung diseases
DE69939388D1 (de) * 1998-09-24 2008-10-02 Innogenetics Nv Identizierung von microorganismen,die akute atemwegsinfektionen verursachen
JP2002540801A (ja) * 1999-04-02 2002-12-03 インタールーキン ジェネティックス インク 間質性肺疾患の危険性の予測
CA2387089A1 (en) * 1999-11-10 2001-05-17 Mondobiotech Sa Interferon gamma for the treatment of asthma
JP2003513681A (ja) * 1999-11-12 2003-04-15 マキシゲン・ホールディングス・リミテッド インターフェロンガンマ・コンジュゲート
EP1455813B1 (en) * 2001-12-18 2015-07-15 mondoBIOTECH AG Interferon gamma in combination with a diagnostic array for use in the improved treatment of idiopathic pulmonary fibrosis

Also Published As

Publication number Publication date
CA2470763A1 (en) 2003-06-26
US20060270618A1 (en) 2006-11-30
CN1620309A (zh) 2005-05-25
EP1455813A2 (en) 2004-09-15
EP1455813B1 (en) 2015-07-15
US20090142301A1 (en) 2009-06-04
AU2002347182A1 (en) 2003-06-30
JP2005528082A (ja) 2005-09-22
WO2003051388A3 (en) 2003-10-30
NO20033642L (no) 2003-10-17
NO20033642D0 (no) 2003-08-15
WO2003051388A2 (en) 2003-06-26

Similar Documents

Publication Publication Date Title
BR0207310A (pt) Composição farmacêutica de interferon gama ou de pirfenidona com diagnósticos moleculares para o melhor tratamento de doenças pulmonares intersticiais
Wilding et al. Once-weekly semaglutide in adults with overweight or obesity
Courneya et al. Physical exercise and quality of life following cancer diagnosis: a literature review
Jia et al. Rickettsia sibirica subspecies sibirica BJ-90 as a cause of human disease
Brewer et al. Cocaine abuse: dermatologic manifestations and therapeutic approaches
Chandnani et al. Group C Streptococcus causing rheumatic heart disease in a child
Florea et al. Review of the pharmacodynamics of antibiotic use in animal food production
Pawelczyk et al. Pegylated interferon α and ribavirin therapy may induce working memory disturbances in chronic hepatitis C patients
Kang et al. A study on physical activity and related factors to physical activity for the elderly with diabetes mellitus
ES2915909T3 (es) Citicolina para mejorar la función motora
Wilde et al. Use of a disease-characteristic questionnaire identified pain and cramps and neuro-vegetative symptoms as significantly elevated and affected by medication in mainly well-controlled hypoparathyroid patients
Kumar et al. Serotonin syndrome while switching antidepressants
Yoo Verbal Working Memory Decline After COVID-19 in 20s
Lyle Medical School Watercooler Newsletter-January 7, 2022
Bawne et al. Case report on Infective endocarditis with supravalvular aortic stenosis
Endeman et al. Influence of old age on survival after prolonged mechanical ventilation
Sulzer Device Design Principles in Pediatric Rehabilitation: Insights From The Dual Role of A Parent and A Rehabilitation Engineer
Oral et al. Revisiting the management of fatigue in multiple sclerosis in the context of rehabilitation: a narrative review of current evidence
Bagic et al. Iatrogenic arsenic induced Mees' lines
Nielsen et al. Cystic hygroma: OK-432 is superior to surgery
Raghav In-depth research highlighting the advantages of engaging in physical activity
Kauffeldt et al. Identifying effective physical activity guideline dissemination and implementation strategies on health care professionals in a cancer care context: A systematic review
Moncrieff et al. The Disease-Centred Model of Drug Action in Psychiatry
Klewer et al. Quality of life in patients with multiple sclerosis living as single
Samaria et al. Profile of Nosocomial Pneumonia in Patients with Acute Exacerbation of COPD.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B25A Requested transfer of rights approved

Owner name: MONDOBIOTECH LABORATORIES ANSTALT (LI)

Free format text: TRANSFERIDO DE: MONDOBIOTECH INTERFERON SA

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]